The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | DCEP and bendamustine/prednisone as salvage for refractory MM
Ravi Vij, MD, MBA, Washington University Medical School, St Louis, MO, outlines the use of dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma (MM). Dr Vij goes on to discuss the choice between an antibody-drug conjugate, or CAR-T cell therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
